ASSEMBLY BIOSCIENCES,INC. (NASDAQ:ASMB) Files An 8-K Regulation FD DisclosureItem 7.01
Assembly Biosciences, Inc. (the “Company”) is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, that the Company intends to use from time to time in meetings with investors and others beginning on June 20, 2018. The corporate presentation will also be available on the Company’s website at https://investor.assemblybio.com/events-presentations.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|Item 9.01||Financial Statements and Exhibits.|
The following exhibit relating to Item 7.01 shall be deemed furnished and not filed.
ASSEMBLY BIOSCIENCES, INC. ExhibitEX-99.1 2 tv496821_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 R&D Day Hepatitis B Program June 20,…To view the full exhibit click
About ASSEMBLY BIOSCIENCES,INC. (NASDAQ:ASMB)
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions. The Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections.